Open Nav

Cyclenium Pharma

  • Helmut Thomas, Cyclenium Pharma

Present macrocycle technology and introduce lead programs

  • Date:Thursday, October 18
  • Time:11:30 AM - 11:45 AM
  • Room:Olympic
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Private company, using proprietary, orally bio-available and brain penetrable, small-molecule macrocycle technology in the discovery of drugs against difficult targets. Advanced lead programs in viral (pan-flavivirus protease inhibitors for the treatment of Dengue, Zika, WNV and JEV infections) and CNS diseases (biased signaling delta-opioid receptor agonists for the treatment of anxiety disorders including PTSD) as well as cystic fibrosis. Cyclenium is seeking A-round financing for the advancement of flavivirus program to IND and clinical Phase 1.
  • Company
  • Company HQ City:Montreal, QC
  • Company HQ Country:Canada
  • Company HQ State:Quebec
  • CEO/Top Company Official:Helmut Thomas, PhD, DABT
  • Year Founded:2013
  • Main Therapeutic Focus:Infectious Diseases
  • Lead Product in Development :pan-flavivirus protease inhibitor
  • Development Phase of Primary Product:Discovery
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :3
  • Previous and Current Investors:N/A
  • Size of Last Investment Round:N/A
  • Total Amount Raised to Date, In All Rounds:0
Helmut Thomas
Cyclenium Pharma